Ray 69 worked as a supplier of marketing goodies to the international pharma industry for his whole working life. Retired wealthy by taking candy from the dummies that populate the industry. Even now while they proclaim to know the big pharma model is bust they still haven't got the guts to make the radical jump into the new world
I use a portfolio based strategy (by which I mean I look at a group of related securities in order to give my analysis context, rather than look at one stock at a time) and I use analysis metrics that are appropriate for the group. The metrics can range from financial statement analysis, to statistical analysis, to qualitative reviews. Sometimes I experiment with new methods, but I will disclose that.
This framework keeps me objective and helps me find the best and worst of a group . Sometimes it leads to an inconclusive result if stocks are doing well by some measures and poorly by others.
I follow up on a periodic basis on the recommendations I make and I will usually invest my own money after I submit an article for publication.
I'm the editor of UKValueInvestor.com, an investment website and monthly newsletter where I write about building high yield, low risk portfolios.
My book, “The Defensive Value Investor”, covers my investment strategy in detail.
Prior to co-founding Paul Kimmins Investments, LP, Paul was an executive in the Transaction Advisory Services team at Ernst & Young where he managed and reviewed asset valuation primarily for publicly traded Fortune 500 corporations. Prior to joining Ernst & Young, Paul was a Portfolio Manager within Key Private Bank, the wealth management arm of KeyBank. In this role, Paul personally managed and invested over $220 million across equities, fixed income and alternatives asset classes. In addition, Paul served as a voting member of the Equity Research Team, providing investment recommendation on the Energy, Technology, Utilities and Materials sectors.
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Uncovering select special situation stocks.
California Real Estate Broker
CEO and President of Gibralter Financial and Real Estate Services from 2001 to 2008.
CEO of All Valley Mortgage 1993-1995
Private investor, Author and trader from 1999 to present.
I am a private investor from the Netherlands. I have a very long term view and focus on stable, dividend-paying investments. My favorite holding period is forever, but I am looking for interesting growth stocks now and then. I am writing for Seeking Alpha because I like to share my insights and enjoy the interaction about investing ideas. My writing is mostly about stocks I own and know a lot about. I am most interested in the consumer staples/discretionary, the energy and the industrial conglomerates markets.
On the picture you can see my cat. I like to think that my investing mimics his behavior: most of the time not doing a lot, finding the best places to lie down (enjoying solid dividend-paying investments). But sometimes for a brief period of time he can become very agile and active, just like what I should do when I notice great investing opportunities (though I'm skeptical about market timing).
Avisol Capital Partners runs the Total Pharma Tracker Seeking Alpha Marketplace service. This is managed by Dr Asok Dutta, BVScAH and Dr Udaya Kumar Maiya, MD Oncologist. The service offers end-to-end research on both investing and trading ideas everyday, and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked.
Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.
If you want to check out our service, go here - https://seekingalpha.com/author/avisol-capital-partners/research
Disclaimer - we are not investment advisors.
I'm 32, invest in the light of the Austrian economic tradition, which in today's environment means mostly precious metals and mining stocks using cycles and sentiment as timing mechanisms. ETF's, options, I also own some physical. I've been doing this independently for 3 years. I reserve a small chunk of my portfolio for speculating in biotech and technology where I believe appropriate.
Strong Bio is a growth-focused analyst seeking identification of unique investment opportunities in biotechnology that arise as high probability market niche innovation or expansion based on scientific peer-reviewed evidence supportive of novel mechanism(s) of action. By diligently screening investment candidates in multiple biotechnology sectors, initial position recommendations and reinforcing position pricing profiles can be systematically evaluated citing fundamental trends for investors to exploit. If you would like to request that Strong Bio publish an article on a company of interest, please request by private message. Strong Bio reminds the reader that investment in biotechnology can be considered high risk, and diversification of assets is a necessity. Strong Bio is a personal branding of F. Thomas Crump, Ph.D., in an attempt to communicate with a biotechnology stock club that got too large to communicate with by text. Strong Bio mobile app under construction.
I'm a self-directed investor who shares my experience in investing. I read, learn, and apply every day.
I write about value, dividend, and growth investing from the perspective of a Canadian. I invest in individual stocks on the US stock exchanges and the Toronto Stock Exchange.
I also offer an exclusive Marketplace service, DGI Across North America, which updates the buy targets of quality U.S. and Canadian dividend-growth stocks every month.
Learn more about the Small Cap model portfolio and the Prudent Biotech model portfolio at Graycell Advisors
Besides being an Analyst on both the Buyside and Sellside, the author has worked in Corporate Strategy and Finance roles for technology services companies and has now been publishing risk-adjusted return-driven quantitative model portfolios for many years at Graycell Advisors. More about the author can be learned here.
During 2016, the Graycell Small Cap Portfolio was up +71% compared to benchmark Russell 2000 Index gain of +19%. The Prudent Biotech Portfolio was up +7%, compared to Biotech Index (IBB) decline of -21% in 2016. In 2017, the outperformance continued, and so in 2018. Recent performance numbers are available here for Graycell Advisors and here for Prudent Biotech.
You are invited to take a look at our website for Samples, Performance, Philosophy, and Approach, and decide if the Biotech and Small Cap products can contribute to your investment objectives.
You can even Register for a Free Monthly Pick from the Biotech as well as Small Cap model portfolios.
Any questions, please write to Support @ GraycellAdvisors .com or use the Contact Form.
Graycell Advisors and related entities are not a Registered Investment Advisor (RIA). Nothing here or on the site constitutes a personalized investment recommendation, and stocks mentioned in the reports/articles/comments may be now or in the past, part of the portfolios recommended by Graycell Advisors and related entities. All opinions expressed are subject to change as new information develops, and no updates will be provided on model portfolios unless you are a subscriber. In addition, even though the author may not have a personal position in the stock names discussed, positions in such stocks may exist within related family and associates accounts.
The Shock Exchange has a B.A. in economics and MBA from a top 10 business school. He has over 10 years of M&A / corporate finance experience. Currently head the New York Shock Exchange, financial literacy program based in Brooklyn, NY.
His book, "Shock Exchange: How Inner-City Kids From Brooklyn Predicted the Great Recession and the Pain Ahead", predicted pain ahead for the U.S. economy and financial markets.
In 2014 the law firm of Kirby, McInerney, LLP brought a class action lawsuit against Molycorp, Inc. for "materially misleading statements" in its financial statements. Kirby, McInerney used investigative journalism from the Shock Exchange to buttress its case. That's the discipline the Shock Exchange brings to every situation he covers for SA.
Midstream professional with a focus on crude and product pipelines. Market Analysis, Project Analysis, Competitive Analysis, and Cash Flow Analysis are a few of my favorite things. Some exposure to other midstream logistics assets.
Over 30 years working in financial services industry that included working for a large mutual fund company and private wealth management firms. Worked in investment communications/marketing role supporting fund managers and interfacing with clients. Experience includes market analysis, asset allocation, manager analysis, portfolio analysis and stock selection.
I currently help students understand fundamental analysis of equities and how to explore the use of Bloomberg terminals for doing meaningful research. Recently I've been covering cryptocurrencies more because the field is exciting and not well researched. I've slowed my writing on stocks due to the nature of my investment process. I look at earnings transcripts, do ratio analysis and sentiment analysis, and look at price action before I buy. These are often not enough to fill a detailed article like the ones I was writing and I would rather not publish weak pieces. I still hope to give my insights on equities occasionally (likely through blog posts), but will be moving to cover the CryptoSphere more. If you're interested in cryptocurrencies, even just to learn more, I hope you'll stick around!
James has degrees in both Economics and Political Science. He is a small business owner with several years of past political experience and 17 years of active investing. Starting in 2018 the vast majority of James' work will be exclusive to Value Investor's Edge. VIE is a top-rated research service dedicated to offering actionable trades and strategic income opportunities. We now cover a variety of deep value and income-driven sectors, while maintaining our focus and very profitable record of shipping industry coverage. Members receive exclusive access to over a dozen reports per month, including regular shipping and commodity macro analysis from James Catlin, exclusive content by top-tier deep value analyst J Mintzmyer, industrial and MLP ideas from Michael Boyd and international insights from Ian Bezek. This winning team has developed a dedicated following of highly knowledgeable investors and industry professionals who also share their own thoughts and ideas. For more information on Value Investor's Edge, simply click here.
Gaurao is an MBA from Wales university and an engineering graduate from Mumbai university. He is involved in international trade and has been passionately tracking global equity markets for more than 7 years. He has been focusing mainly on spotting long term value investments in biotechnology, pharmaceutical, health insurance, hospital, and medical device sectors.
Having always been a learning machine, I speak five languages, have worked as a sales agent, project manager, translator, computer consultant, software engineer, built a house with my own hands, published books and essays on literature, philosophy and art, have written for magazines of various kinds in different countries.
After retiring early in 2004, little by little, I have become a fund manager for some friends and myself, following the principles of value investing laid out by Benjamin Graham, Phil Fisher, Charlie Munger and Warren Buffett.
In 2015 I won the Seeking Alpha Contrarian Contest and have been a regular contributor to Seeking Alpha Pro right from the start.
I strive to gather above-average knowledge about my stock picks. As this takes many hours, despite managing my portfolio full-time, you should not expect me to throw out new ideas each and every week.
One can't be an expert on everything, but can try to acquire deep knowledge about a careful selection of businesses. Only knowledge can provide the required conviction to profit from temporary market inefficiencies (i.e. buy into a sell-off).
If you want to learn more about my research process, take a look at my Marketplace service "Stability & Opportunity". It offers access to the totality of my research notes and updates several times daily on average.
Legal Disclaimer: My contributions to Seeking Alpha, or elsewhere on the web, are to be construed as personal opinion only and do NOT constitute investment advice. An investor should always conduct personal due diligence before initiating a position. Provided articles and comments should NEVER be construed as official business recommendations. In efforts to keep full transparency, related positions will be disclosed at the end of each article to the maximum extent practicable. My own trades are reported in my subscription service "Stability & Opportunity", but this cannot always be guaranteed due to technical constraints.
My premium service is a research and opinion subscription. No personalized investment advice will ever be given. I am not registered as an investment adviser, nor do I have any plans to pursue this path. No statements should be construed as anything but opinion, and the liability of all investment decisions reside with the individual. Although I do my utmost to procure high quality information, investors should always do their own due diligence and fact check all research prior to making any investment decisions. Any direct engagements with readers should always be viewed as hypothetical examples or simple exchanges of opinion as nothing is ever classified as “advice” in any sense of the word.
I have written 2 dutch books on value investing (search bol.com for "ruerd heeg"). As a mathematician (Ph.D.) I use quantitative strategies with statistically extremely high returns: net-nets and companies with low Enterprise Value/Earnings before Tax & Interest (EV/EBIT). When ranking on several metrics the 30-50 best stocks have 20-30% average annual returns. Since such stocks are rare I invest globally. See my article "Use Your Extraordinary Edge With These 2 Investment Strategies" (author's picks left below). Get the free trial of my Marketplace newsletter to learn more.
Independent investor and stock analyst at Matrixtrade.com. Trend follower and market timer. Correlations and analogues. All time frames, all instruments.....wherever I see an edge I trade it.
I am a self-taught investor. As a member of an investment club, I provide the majority of research to the club. When I started writing for SA, the club was interested in stocks offering growth at a reasonable price (GARP) and stocks that were undervalued. We have since adopted a dividend growth investing (DGI) strategy. We search for GRAVY - our acronym for "GR"owth "A"bility, "V"alue and "Y"ield.
I am very interested in other active investors critiquing my research. I believe this critique will make me a better investor for my own interests as well as the club's.
As a chemist and part-time investor, I focus on technology and natural-resource related businesses and macroeconomic events that influence their prices. I use past trends and technological developments to make decisions on companies that I would invest in. My point of view as a chemist occasionally allows a deeper look at some of the fundamentals of some companies that base their technology on chemical principles.
About "Le Statisticien" -- My retirement investment fund has been a self-directed one for many years (that is, I am my own fund manager), during which time I have occasionally traded both stocks and options and have managed to avoid losing my shirt across bear and bull markets, while not becoming financially wealthy. I have been an amateur programmer for many years, working in several languages, and am now resuming past work on micro-simulation models both for professional work involving demographic statistics, and for my investment program (sophisticated types of back-testing using real historical data for stock and option price movements). My professional work has lead to deep digging into literature on personal conceptions of and responses to risk management challenges, and I have published articles and given occasional seminars that deal with related theoretical aspects of personal risk management.
Creator of the Core Value Portfolio. The goal is simple but not easy. By shooting for an extraordinary goal of compounding capital at 20% annually over the long-term, the portfolio embraces concentration and goes through dramatic swings. Those without conviction will sell when positions don't go their way, but the Core Value Portfolio always takes advantage when the market is wrong.
The Core Value Portfolio has significantly outperformed the market since its inception, but it also experienced extended periods of underperformance. This is a sacrifice that I'm willing to make for the sake of achieving superior returns over the long-term.
"No one can know everything. But still try."
Contact: generalexpert86 [g]mail